Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Frontline ibrutinib + rituximab better than gold for CLL in young patients

Pearl Toh, 2 hours ago

First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.

Rivaroxaban may reduce VTE risk in cancer patients

Roshini Claire Anthony, 6 hours ago

Rivaroxaban may help reduce the incidence of venous thromboembolism (VTE) and VTE-related deaths in patients who are receiving systemic treatment for metastatic malignancies, but only if they keep taking the anticoagulant, according to findings of the phase IIIb CASSINI trial.

Brentuximab vedotin + CHP doubles PFS over CHOP in CD30+ peripheral T-cell lymphoma

Roshini Claire Anthony, Yesterday

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

Maintenance olaparib provides survival advantage in mutated ovarian cancer

Jairia Dela Cruz, Yesterday

The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.

Direct switch to IND/GLY from SFC improves predose FEV1, FVC in COPD patients

Yesterday

A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.

Podcast: Dr Steven Horwitz highlights the ECHELON-2 findings which showed a doubled PFS with brentuximab vedotin + CHP vs CHOP in patients with CD30-expressing peripheral T-cell lymphoma

Yesterday

Podcast: Dr Steven Horwitz highlights the ECHELON-2 findings which showed a doubled PFS with brentuximab vedotin + CHP vs CHOP in patients with CD30-expressing peripheral T-cell lymphoma.

Podcast: Dr Ceri Bygrave explains how early relapse after stem cell transplant for myeloma is a marker of high-risk disease and a predictor of poor overall survival

Yesterday

Podcast: Dr Ceri Bygrave explains how early relapse after stem cell transplant for myeloma is a marker of high-risk disease and a predictor of poor overall survival.

Targeted Immunotherapy against PD-L1 in NSCLC

21 Nov 2018

Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.

A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin

19 Sep 2018

In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.^1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.⁴ Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.⁵

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018

At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

Brentuximab vedotin + CHP doubles PFS over CHOP in CD30+ peripheral T-cell lymphoma

Roshini Claire Anthony, 11 Dec 2018

Podcast: Dr Steven Horwitz highlights the ECHELON-2 findings which showed a doubled PFS with brentuximab vedotin + CHP vs CHOP in patients with CD30-expressing peripheral T-cell lymphoma

11 Dec 2018

Podcast: Dr Steven Horwitz highlights the ECHELON-2 findings which showed a doubled PFS with brentuximab vedotin + CHP vs CHOP in patients with CD30-expressing peripheral T-cell lymphoma.

Podcast: Dr Ceri Bygrave explains how early relapse after stem cell transplant for myeloma is a marker of high-risk disease and a predictor of poor overall survival

11 Dec 2018

Podcast: Dr Ceri Bygrave explains how early relapse after stem cell transplant for myeloma is a marker of high-risk disease and a predictor of poor overall survival.

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh, 07 Dec 2018

Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

MURANO solidifies venetoclax-rituximab combo for relapsed/refractory CLL

Roshini Claire Anthony, 07 Dec 2018

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

Apalutamide equally beneficial in Asians with nmCRPC

Elvira Manzano, 05 Dec 2018

Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!